1 0 6 2 volume 15 | number 9 | SePTember 2009 nature medicine l e t t e r s Recent work has shown that primary cilia are essential for Hedgehog (Hh) signaling during mammalian development 1-9 . It is also known that aberrant Hh signaling can lead to cancer 10 , but the role of primary cilia in oncogenesis is not known. Cerebellar granule neuron precursors (GNPs) can give rise to medulloblastomas, the most common malignant brain tumor in children 11 . The primary cilium and Hh signaling are required for GNP proliferation 8,12-15 . We asked whether primary cilia in GNPs have a role in medulloblastoma growth in mice. Genetic ablation of primary cilia blocked medulloblastoma formation when this tumor was driven by a constitutively active Smoothened protein (Smo), an upstream activator of Hh signaling. In contrast, removal of cilia was required for medulloblastoma growth by a constitutively active glioma-associated oncogene family zinc finger-2 (GLI2), a downstream transcription factor. Thus, primary cilia are either required for or inhibit medulloblastoma formation, depending on the initiating oncogenic event. Remarkably, the presence or absence of cilia was associated with specific variants of human medulloblastomas; primary cilia were found in medulloblastomas with activation in HH or WNT signaling but not in most medulloblastomas in other distinct molecular subgroups. Primary cilia could serve as a diagnostic tool and provide new insights into the mechanism of tumorigenesis.
Abnormal activation of Hh signaling, through loss of the Hh receptor Patched1 (Ptch1) or activation of Smo, induces medulloblastomas in mice [16] [17] [18] [19] [20] [21] . To induce medulloblastoma, we expressed constitutively active Smo (SmoM2) in GNPs using a human glial fibrillary acidic protein promoter-driven Cre (GFAPCre) 20 . By postnatal day 10 (P10), GFAPCre;SmoM2 fl/+ mice developed medulloblastoma (n = 7) ( Fig. 1a) . In these tumors, SmoM2 fused with yellow fluorescent protein (YFP) localized to primary cilia that are associated with the basal body ( Fig. 1b) . To investigate whether SmoM2-driven medulloblastoma formation requires primary cilia, we removed primary cilia from GNPs expressing SmoM2, using a conditional allele of Kif3a, which encodes a subunit of the kinesin-II motor essential for ciliogenesis [22] [23] [24] . The removal of Kif3a and the consequent loss of cilia completely blocked tumorigenesis (n = 7) (Fig. 1a) .
The cerebella of the GFAPCre;SmoM2 fl/+ ;Kif3a fl/fl mice resembled those of GFAPCre;Kif3a fl/fl mice (Fig. 1a) , which fail to expand GNPs 8, 12 . Loss of Ift88, encoding intraflagellar transport 88 homolog, another gene essential for ciliogenesis 25, 26 , in GFAPCre;SmoM2 fl/+ ; Ift88 fl/fl mice also blocked tumorigenesis driven by SmoM2 ( Supplementary Fig. 1a) .
At embryonic day 16 (E16) , when the number of GNPs is not affected by removing cilia 8 , the external granule cell layer (EGL) was already expanded, with many proliferating cells in GFAPCre;SmoM2 fl/+ mice but not in GFAPCre;SmoM2 fl/+ ;Kif3a fl/fl mice ( Fig. 1c,d ), suggesting that SmoM2 requires Kif3a to initiate the aberrant GNP expansion and medulloblastoma. A similar requirement of cilia for SmoM2-driven expansion of GNPs has been observed in the hippocampal dentate gyrus 4 .
Activated Smo converts Gli2 into a transcriptional activator and inhibits the formation of Gli3 repressors that form constitutively in the absence of Hh signaling 27 . We hypothesized that constitutively active Gli2 could induce medulloblastomas in the absence of primary cilia. To test this hypothesis, we used CLEG2 transgenic mice that, upon Cre-mediated recombination, express a constitutively active human GLI2 that lacks the N-terminal repressor domain (GLI2∆N) 28, 29 . Unexpectedly, none of the GFAPCre;CLEG2 fl/+ mice (n = 14) developed medulloblastoma (Fig. 2) , albeit two had another type of tumor (detailed below). To our surprise, unlike in GFAPCre;CLEG2 fl/+ mice, removal of primary cilia in GFAPCre;CLEG2 fl/+ ;Kif3a fl/fl mice induced medulloblastomas between P11 and P30 (n = 11) ( Fig. 2) . Tumors in GFAPCre;CLEG2 fl/+ ;Kif3a fl/fl mice contained two types of cells frequently segregated into distinct zones: cells with darkly stained nuclei and lightly stained cytoplasm (type 1) and cells with large nuclei and highly eosinophilic cytoplasm (type 2) ( Fig. 2b,c) . Both cell types were actively proliferating as determined by BrdU incorporation ( Fig. 2f ) and expressed Gli1, suggesting active Hh signaling ( Supplementary Fig. 2 ). The type 1 tumor cells were indistinguishable from those in SmoM2-driven medulloblastoma 17, 18, 20 and were reminiscent of classic medulloblastoma cells: small round cells with high nuclear-to-cytoplasmic ratio. Type 1 cells showed immunohistological characteristics of medulloblastoma similar to those in SmoM2 tumor: neuronal (βIII tubulin), glial (GFAP and oligodendrocyte transcription factor-2 (Olig2)), GNP (paired box gene-6 (Pax6)), and granule neuron (zinc finger protein of the cerebellum-1 l e t t e r s (Zic1)) markers ( Supplementary Fig. 3 ). GFAPCre;CLEG2 fl/+ ; Kif3a fl/fl and GFAPCre;SmoM2 fl/+ mice also had very similar gene expression profiles ( Fig. 2h) , including upregulation of Hh-responsive genes characteristic of medulloblastoma cells (Gli1, Gli2, Ptch1, Ptch2, Mycn (encoding N-Myc), Ccnd2, (encoding cyclin D2) Atoh1 (encoding atonal homolog-1) and Bmi1 (encoding Bmi1 polycomb ring finger oncoprotein)). The expression of Gli3 and Wif1 (encoding Wnt inhibitory factor-1) differed between the two tumors, probably owing to the presence of type 2 tumor cells in GFAPCre;CLEG2 fl/+ ;Kif3a fl/fl mice; type 2 tumor cells downregulated Gli3 and upregulated Wif1 ( Fig. 2h and detailed below). Type 2 tumors lacked immunohistological characteristics of medulloblastoma markers ( Supplementary Fig. 3 ), but expressed Sox2 (sex determining region Y-box 2) (data not shown), suggesting that these are not medulloblastomas. We also found type 2 tumors outside of the cerebellum, suggesting that these cells have a different origin ( Supplementary Fig. 4a ). Both tumor types lacked primary cilia ( Supplementary Fig. 5 ). Similar to loss of Kif3a, loss of Ift88 promoted tumor formation containing both type 1 and type 2 tumor cells in GFAPCre;CLEG2 fl/+ ;Ift88 fl/fl mice ( Supplementary Fig. 1b) .
Later in life, GFAPCre;CLEG2 fl/+ mice developed only type 2 tumors, which we found throughout central nervous system ( Supplementary  Fig. 4b ), and they lived significantly longer than GFAPCre; CLEG2 fl/+ ;Kif3a fl/fl mice (P < 0.0001, n = 19) ( Fig. 2g) . These tumors expressed high levels of Hh-responsive genes (Gli1, Gli2, Ptch1, Ptch2, Mycn and Ccnd2) and Wnt-responsive genes (Axin2 and Wif1) but not genes associated with GNPs and medulloblastoma (Atoh1 (ref. 19 ) and Bmi1 (ref. 30)) ( Fig. 2h) . Type 2 tumors in GFAPCre;CLEG2 fl/+ mice had primary cilia, excluding the possibility that they may have originated from cells that spontaneously lost primary cilia ( Supplementary Fig. 5 ). Thus, loss of cilia was required for medulloblastoma development driven Fig. 2a-c,g) .
The above results suggest that loss of primary cilia is required for GLI2∆N-driven medulloblastoma development, which is in striking contrast to their requirement for SmoM2-driven tumorigenesis. One possible explanation for these opposite roles is that primary cilia are required not only for Smo function but also for Gli3 repressor formation 2,6,7,9 . Consistently, Gli3 repressor level was markedly lower in GFAPCre;CLEG2 fl/+ ;Kif3a fl/fl mice than in wild-type or GFAPCre;CLEG2 fl/+ mice (Fig. 2d) . Gli3 expression was also significantly lower in type 2 tumors in GFAPCre;CLEG2 fl/+ mice ( Fig. 2h) , suggesting that Gli3 might also have an inhibitory role in these tumors. Because homozygosity for the null mutation of Gli3 gene (Gli3 extra toes (Xt)) is embryonic lethal, we removed one copy of Gli3 in mice expressing GLI2∆N (GFAPCre;CLEG2 fl/+ ;Gli3 Xt/+ ) to test whether Gli3 has an inhibitory effect on GLI2∆N-driven tumorigenesis. GFAPCre;CLEG2 fl/+ ;Gli3 Xt/+ mice developed type 2 tumors and died earlier in life than GFAPCre;CLEG2 fl/+ mice (P < 0.02, n = 18) ( Fig. 2g and Supplementary Fig. 6 ). Thus, loss of one copy of Gli3 induces earlier development of the type 2 tumors in the presence of primary cilia, supporting our inference that Gli3 repressors may mediate the inhibitory function of primary cilia in tumorigenesis driven by GLI2∆N. Of note, GFAPCre;CLEG2 fl/+ ;Gli3 Xt/+ mice did not develop medulloblastoma, possibly owing to the repressor activity of one copy of wild-type Gli3. Loss of primary cilia might also interfere with other signaling pathways that contribute to medulloblastoma development.
Whereas SMOM2 mutations have been observed in one case of human medulloblastoma 31 , activating mutations in GLI transcription factors have not been described in medulloblastoma. Thus, our mouse models reveal key roles of primary cilia in tumorigenesis but might not reflect on the behavior of this organelle in human cases. To determine whether our observations in mice are relevant to human tumors, we analyzed 38 human medulloblastomas for the presence of cilia. The presence of primary cilia was significantly associated with desmoplastic medulloblastoma (five of six tumors were ciliated; P < 0.02); whereas the absence of cilia was significantly associated with anaplastic medulloblastoma (only one of nine tumors was ciliated; P < 0.05) ( Fig. 3a and Table 1 ). Twenty-four of these samples were analyzed previously for gene expression profiling 32 . Notably, in these 24 samples, we identified cilia almost exclusively in tumors that had activation in either HH or WNT signaling (P < 0.0001, Table 1 ). Two of the four tumors with active HH signaling had inactivating mutations in PTCH1 (ref. 32) , which functions upstream of SMO and primary cilia 5 .
Our results suggest that primary cilia can be either permissive or inhibitory for tumor formation, depending on the underlying oncogenic events (Fig. 3b) . We found that some subsets of human medulloblastomas have primary cilia, whereas others do not. Our mouse models predict that medulloblastomas with activating mutations in HH signaling components downstream of the cilia will grow only when the cilia are not present. Notably, all of the observed human medulloblastomas with high HH signaling activity had primary cilia. This suggests that medulloblastomas with high HH signaling in humans largely result from mutations upstream of the primary l e t t e r s cilia, such as mutations in PTCH1. Oncogenic mutations in downstream molecules, including GLI transcription factors, which would require loss of repressor activity mediated by the cilia, are rare 11 . A recent study identified rare amplifications of GLI1 and GLI2 genes in medulloblastomas 33 , but it is not known whether these tumors are ciliated. Analyses of more medulloblastomas both for oncogenic mutations and for the presence or absence of primary cilia will be necessary to delineate the role of cilia in human medulloblastoma. Of note, all of the observed human medulloblastomas with high WNT signaling had primary cilia, and all of these tumors had mutations in CTNNB1, which encodes β-catenin. It is possible that primary cilia are also involved in the WNT signaling pathway [34] [35] [36] or that oncogenic WNT activation requires concomitant signaling through primary cilia to induce medulloblastoma. Our observations suggest that the presence of primary cilia is fundamental for tumor diagnosis and possibly for the development of new treatments. HH signaling mutations found in medulloblastomas, loss of PTCH1 and activation of SMO all act upstream of primary cilia 2,4-9 . Ciliated medulloblastomas showing high HH signaling would be susceptible to treatments that target primary cilia. The loss of cilia in subgroups of medulloblastomas suggests that tumor repressor functions mediated through primary cilia might serve as therapeutic targets to inhibit tumor growth. GLI3 is a strong candidate, but primary cilia could have multiple repressor activities. Understanding the role of primary cilia in normal and oncogenic signaling may lead to better understanding of tumor development and treatment not only in medulloblastomas but also in other tumors 37 .
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